Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 16, 2016 22:02:47 GMT -5
What makes you think Omeros is going to hit the protein coupled receptors delineated with: (?)
I wasnt speculating and supporting lakers guess. I was just adding the link so people can further read about gpcr. if you ask me who RLS , I would say Veritas.
|
|
|
Post by peppy on May 16, 2016 22:23:44 GMT -5
What makes you think Omeros is going to hit the protein coupled receptors delineated with: (?)
I wasnt speculating and supporting lakers guess. I was just adding the link so people can further read about gpcr. if you ask me who RLS , I would say Veritas. Thank you seeker
|
|
|
Post by peppy on May 17, 2016 3:42:33 GMT -5
I wasnt speculating and supporting lakers guess. I was just adding the link so people can further read about gpcr. if you ask me who RLS , I would say Veritas. Thank you seeker This is what I read in your reply seeker. I do not think it was my dyslexia. It would be a dream come true for share price. Note date: December 7, 2015
MOUNTAIN VIEW, Calif. — Google Life Sciences, the Silicon Valley giant’s new foray into health and medicine, announced a new name Monday that slips easily off the tongue but might sound antiquated to a high-tech, life-sciences ear: Verily.
“Verily, I swear,” as Shakespeare wrote in Henry VIII.
The word means “truly” or “certainly.” It dates back to 13th century Middle English and fell out of common use … well, a while ago. It often pops up, however, in the still very popular King James Bible. www.statnews.com/2015/12/07/verily-google-life-sciences-name/ The company was spun off from Google a few months ago within Alphabet, a holding company for Google itself and affiliated entities. Verily has built a multidisciplinary team of doctors, engineers, chemists, and data gurus to tackle big mysteries of disease prevention and health. As a sign of seriousness about the bigger picture, Verily has a staff philosopher. “We have to understand the ‘why’ of what people do,” Conrad said. “A philosopher might be as important as a chemist.”
Verily evolved out of a Google-designed contact lens for diabetics that continuously monitors glucose in tears. The company is targeting health issues that affect millions, such as cardiovascular disease, cancer, and mental health. It’s producing other wearable medical devices and miniature sensors, such as a nanoparticle-based diagnostic tool to detect cancer or other ailments at very early stages.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 17, 2016 5:53:09 GMT -5
This is what I read in your reply seeker. I do not think it was my dyslexia. It would be a dream come true for share price. Note date: December 7, 2015
MOUNTAIN VIEW, Calif. — Google Life Sciences, the Silicon Valley giant’s new foray into health and medicine, announced a new name Monday that slips easily off the tongue but might sound antiquated to a high-tech, life-sciences ear: Verily.
“Verily, I swear,” as Shakespeare wrote in Henry VIII.
The word means “truly” or “certainly.” It dates back to 13th century Middle English and fell out of common use … well, a while ago. It often pops up, however, in the still very popular King James Bible. www.statnews.com/2015/12/07/verily-google-life-sciences-name/ The company was spun off from Google a few months ago within Alphabet, a holding company for Google itself and affiliated entities. Verily has built a multidisciplinary team of doctors, engineers, chemists, and data gurus to tackle big mysteries of disease prevention and health. As a sign of seriousness about the bigger picture, Verily has a staff philosopher. “We have to understand the ‘why’ of what people do,” Conrad said. “A philosopher might be as important as a chemist.”
Verily evolved out of a Google-designed contact lens for diabetics that continuously monitors glucose in tears. The company is targeting health issues that affect millions, such as cardiovascular disease, cancer, and mental health. It’s producing other wearable medical devices and miniature sensors, such as a nanoparticle-based diagnostic tool to detect cancer or other ailments at very early stages.
Verily is not veritas
|
|
|
Post by peppy on May 17, 2016 9:52:55 GMT -5
This is what I read in your reply seeker. I do not think it was my dyslexia. It would be a dream come true for share price. Note date: December 7, 2015
MOUNTAIN VIEW, Calif. — Google Life Sciences, the Silicon Valley giant’s new foray into health and medicine, announced a new name Monday that slips easily off the tongue but might sound antiquated to a high-tech, life-sciences ear: Verily.
“Verily, I swear,” as Shakespeare wrote in Henry VIII.
The word means “truly” or “certainly.” It dates back to 13th century Middle English and fell out of common use … well, a while ago. It often pops up, however, in the still very popular King James Bible. www.statnews.com/2015/12/07/verily-google-life-sciences-name/ The company was spun off from Google a few months ago within Alphabet, a holding company for Google itself and affiliated entities. Verily has built a multidisciplinary team of doctors, engineers, chemists, and data gurus to tackle big mysteries of disease prevention and health. As a sign of seriousness about the bigger picture, Verily has a staff philosopher. “We have to understand the ‘why’ of what people do,” Conrad said. “A philosopher might be as important as a chemist.”
Verily evolved out of a Google-designed contact lens for diabetics that continuously monitors glucose in tears. The company is targeting health issues that affect millions, such as cardiovascular disease, cancer, and mental health. It’s producing other wearable medical devices and miniature sensors, such as a nanoparticle-based diagnostic tool to detect cancer or other ailments at very early stages.
Verily is not veritas www.veritas.com/ I could not make veritas fit the API
|
|
|
Post by cathode on May 17, 2016 10:02:13 GMT -5
|
|
|
Post by agedhippie on May 17, 2016 10:30:53 GMT -5
There is always the possibility that RLS is just RLS.
|
|
|
Post by nylefty on May 17, 2016 10:57:24 GMT -5
There is always the possibility that RLS is just RLS. I'd say the chances of that are about 99.9 percent.
|
|
|
Post by madog365 on May 17, 2016 10:59:49 GMT -5
Another interesting connection between Paul Allen and inhaled insulin to treat dementia/alzheimers. April 26, 2016 - alleninstitute.org/what-we-do/brain-science/news-press/press-releases/allen-institute-releases-powerful-new-data-aging-brain-and-traumatic-brain-injuryThe Allen Institute for Brain Science has announced major updates to its online resources available at brain-map.org, including a new resource on Aging, Dementia and Traumatic Brain Injury (TBI) in collaboration with UW Medicine researchers at the University of Washington, and Group Health. The resource is the first of its kind to collect and share a wide variety of data modalities on a large sample of aged brains, complete with mental health histories and clinical diagnoses...The study samples come from the Adult Changes in Thought (ACT) study, a longitudinal research effort led by Dr. Eric B. Larson and Dr. Paul K. Crane of the Group Health Research Institute and the University of Washington to collect data on thousands of aging adults, including detailed information on their health histories and cognitive abilities...."This study was made possible by the amazing generosity of the ACT participants and their families, incredible collaboration among our partners, and the generosity and vision of the Paul G. Allen Family Foundation,” Who are Dr Larson and Dr Crane? They are the researchers first responsible for studying the link between glucose levels, inhaled insulin, and the brain - Specifically in treating Alzheimers and Dementia. www.psychiatryadvisor.com/alzheimers-disease-and-dementia/inhaled-insulin-improves-memory-dementia-treatment/article/430731/www.ncbi.nlm.nih.gov/pmc/articles/PMC3955123/At the very least we can conclude the Paul Allen is aware of the ACT study since he is the one funding it. Additionally, it is well known that Paul Allen has a personal mission for curing the disease as it has affected him with the death of his mother. "Faye Allen was first diagnosed with Alzheimer’s in 2003, and her battle with the disease was one of the inspirations behind Paul Allen establishing the Allen Institute for Brain Science. Paul Allen earlier this year invested $300 million into the research organization to help investigate the mysteries of the human brain." Could Receptor be the company set up to commercialize the research Paul Allen has been funding for many years? Human trials for this insulin use case are ongoing and some have even concluded. Was Mannkind brought in to provide a specific affordable technospehere inhaler for Nasal insulin due to their expertise in delivering inhaled insulin for diabetics?
|
|
|
Post by peppy on May 17, 2016 11:06:55 GMT -5
Another interesting connection between Paul Allen and inhaled insulin to treat dementia/alzheimers. April 26, 2016 - alleninstitute.org/what-we-do/brain-science/news-press/press-releases/allen-institute-releases-powerful-new-data-aging-brain-and-traumatic-brain-injuryThe Allen Institute for Brain Science has announced major updates to its online resources available at brain-map.org, including a new resource on Aging, Dementia and Traumatic Brain Injury (TBI) in collaboration with UW Medicine researchers at the University of Washington, and Group Health. The resource is the first of its kind to collect and share a wide variety of data modalities on a large sample of aged brains, complete with mental health histories and clinical diagnoses...The study samples come from the Adult Changes in Thought (ACT) study, a longitudinal research effort led by Dr. Eric B. Larson and Dr. Paul K. Crane of the Group Health Research Institute and the University of Washington to collect data on thousands of aging adults, including detailed information on their health histories and cognitive abilities...."This study was made possible by the amazing generosity of the ACT participants and their families, incredible collaboration among our partners, and the generosity and vision of the Paul G. Allen Family Foundation,” Who are Dr Larson and Dr Crane? They are the researchers first responsible for studying the link between glucose levels, inhaled insulin, and the brain - Specifically in treating Alzheimers and Dementia. www.psychiatryadvisor.com/alzheimers-disease-and-dementia/inhaled-insulin-improves-memory-dementia-treatment/article/430731/www.ncbi.nlm.nih.gov/pmc/articles/PMC3955123/At the very least we can conclude the Paul Allen is aware of the ACT study since he is the one funding it. Additionally, it is well known that Paul Allen has a personal mission for curing the disease as it has affected him with the death of his mother. "Faye Allen was first diagnosed with Alzheimer’s in 2003, and her battle with the disease was one of the inspirations behind Paul Allen establishing the Allen Institute for Brain Science. Paul Allen earlier this year invested $300 million into the research organization to help investigate the mysteries of the human brain." Could Receptor be the company set up to commercialize the research Paul Allen has been funding for many years? Human trials for this insulin use case are ongoing and some have even concluded. Was Mannkind brought in to provide a specific affordable technospehere inhaler for Nasal insulin due to their expertise in delivering inhaled insulin for diabetics? Was Mannkind brought in to provide a specific affordable technospehere inhaler for Nasal insulin due to their expertise in delivering inhaled insulin for diabetics? interesting.
|
|
|
Post by cathode on May 17, 2016 11:11:32 GMT -5
There is always the possibility that RLS is just RLS. Matt had said that RLS was an established company, but changed names. Another interesting connection between Paul Allen and inhaled insulin to treat dementia/alzheimers. April 26, 2016 - alleninstitute.org/what-we-do/brain-science/news-press/press-releases/allen-institute-releases-powerful-new-data-aging-brain-and-traumatic-brain-injuryThe Allen Institute for Brain Science has announced major updates to its online resources available at brain-map.org, including a new resource on Aging, Dementia and Traumatic Brain Injury (TBI) in collaboration with UW Medicine researchers at the University of Washington, and Group Health. The resource is the first of its kind to collect and share a wide variety of data modalities on a large sample of aged brains, complete with mental health histories and clinical diagnoses...The study samples come from the Adult Changes in Thought (ACT) study, a longitudinal research effort led by Dr. Eric B. Larson and Dr. Paul K. Crane of the Group Health Research Institute and the University of Washington to collect data on thousands of aging adults, including detailed information on their health histories and cognitive abilities...."This study was made possible by the amazing generosity of the ACT participants and their families, incredible collaboration among our partners, and the generosity and vision of the Paul G. Allen Family Foundation,” Who are Dr Larson and Dr Crane? They are the researchers first responsible for studying the link between glucose levels, inhaled insulin, and the brain - Specifically in treating Alzheimers and Dementia. www.psychiatryadvisor.com/alzheimers-disease-and-dementia/inhaled-insulin-improves-memory-dementia-treatment/article/430731/www.ncbi.nlm.nih.gov/pmc/articles/PMC3955123/At the very least we can conclude the Paul Allen is aware of the ACT study since he is the one funding it. Additionally, it is well known that Paul Allen has a personal mission for curing the disease as it has affected him with the death of his mother. "Faye Allen was first diagnosed with Alzheimer’s in 2003, and her battle with the disease was one of the inspirations behind Paul Allen establishing the Allen Institute for Brain Science. Paul Allen earlier this year invested $300 million into the research organization to help investigate the mysteries of the human brain." Could Receptor be the company set up to commercialize the research Paul Allen has been funding for many years? Human trials for this insulin use case are ongoing and some have even concluded. Was Mannkind brought in to provide a specific affordable technospehere inhaler for Nasal insulin due to their expertise in delivering inhaled insulin for diabetics? This basically goes against everything we know about the partnership and RLS. Namely most of the stated treatment areas the partnership concerns and that RLS specializes in plant extracts.
|
|
|
Post by kbrion77 on May 17, 2016 11:16:13 GMT -5
Bottom line is if they don't figure out a way to increase scripts and volume of Afrezza we will never know who RLS is.
|
|
|
Post by madog365 on May 17, 2016 11:21:17 GMT -5
This basically goes against everything we know about the partnership and RLS. Namely most of the stated treatment areas the partnership concerns and that RLS specializes in plant extracts. Please tell me what part of what we know about RLS my statement goes against? "MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today announced that it has entered into a collaboration and license agreement with a newly formed entity, Receptor Life Sciences, Inc., pursuant to which multiple inhaled therapeutic products will be developed to explore their potential to treat conditions such as chronic pain, neurologic diseases and inflammatory disorders." Plant extracts is a broad category for trademark registration - and not the only category they are registered under. Don't harp on it.
|
|
|
Post by cathode on May 17, 2016 11:42:50 GMT -5
Sorry if I came off mean.
It doesn't cover two of the three stated conditions -- chronic pain and inflammatory disorders.
As far as the plant extracts are concerned -- I think it is about the only thing that can be harped on. I don't understand why anyone wouldn't hang their hat on that...
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 17, 2016 12:22:29 GMT -5
I said veritas pharma due to this veritaspharmainc.com/2016/05/03/health-canada-approval-received/About VERITAS Pharma Inc. Veritas Pharma Inc. is an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy. Using a ‘lean and mean’ approach to product development, the company aims to select candidate cultivars using classical pharmacology techniques and then immediately evaluate them in the clinic to maximize both product value and shareholder return. Veritas’s scientists are an inter-disciplinary team that consists of chemists, pharmacologists, anesthetists, and clinical pharmacologists. Their focus is to use their knowledge to streamline the development of cannabis based treatments to capture considerable market share.
|
|